Price to Book Value Chart

Historical Price to Book Value Data

View and export this data back to 1998. Start Trial.
Date Value
October 02, 2026 3.527
October 01, 2026 3.556
September 30, 2026 3.615
September 29, 2026 3.644
September 28, 2026 3.674
September 25, 2026 3.703
September 24, 2026 3.703
September 23, 2026 3.644
September 22, 2026 3.850
September 21, 2026 3.820
September 18, 2026 3.820
September 17, 2026 3.879
September 16, 2026 3.791
September 15, 2026 3.850
September 14, 2026 4.026
September 11, 2026 3.967
September 10, 2026 4.026
September 09, 2026 4.114
September 08, 2026 4.438
September 04, 2026 4.614
September 03, 2026 4.438
September 02, 2026 4.673
September 01, 2026 4.350
August 31, 2026 4.379
August 28, 2026 4.438
Date Value
August 27, 2026 4.496
August 26, 2026 4.496
August 25, 2026 4.555
August 24, 2026 4.467
August 21, 2026 4.467
August 20, 2026 4.555
August 19, 2026 4.673
August 18, 2026 4.496
August 17, 2026 4.496
August 14, 2026 4.320
August 13, 2026 4.511
August 12, 2026 4.614
August 11, 2026 4.790
August 10, 2026 4.350
August 07, 2026 4.350
August 06, 2026 4.614
August 05, 2026 4.790
August 04, 2026 3.938
August 03, 2026 3.762
July 31, 2026 3.791
July 30, 2026 3.938
July 29, 2026 4.114
July 28, 2026 4.261
July 27, 2026 4.350
July 24, 2026 4.173

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Precigen, Inc. 70.16
Editas Medicine, Inc. 3.821
Agenus, Inc. --
Amgen, Inc. 18.64
BioCryst Pharmaceuticals, Inc. --

Price to Book Value Related Metrics

PS Ratio 3.922
Price 1.20
Earnings Yield -8.72%
Market Cap 770.96M